查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1946503

口服胰岛素市场 - 全球产业规模、份额、趋势、竞争格局、机会及预测（按剂型、胰岛素类型、地区和竞争格局划分，2021-2031年）

Insulin Pills Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, Segmented By Form, By Type of Insulin, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球口服胰岛素市场预计将从 2025 年的 4,000 万美元成长到 2031 年的 1.5 亿美元，复合年增长率为 24.64%。

该市场专注于开发口服胰岛素製剂，旨在使其能够耐受胃酸并在肠道内吸收，为注射治疗提供非侵入性治疗方法。推动此成长的关键因素包括：迫切需要无痛给药方式以提高患者依从性，以及全球糖尿病发生率的不断上升。根据国际糖尿病联盟的数据，到2024年，全球20至79岁的成年人中将有约5.89亿人患有糖尿病，凸显了对便利治疗方案的巨大需求。

市场概览
预测期 2027-2031
市场规模：2025年 4000万美元
市场规模：2031年 1.5亿美元
复合年增长率：2026-2031年 24.64%
成长最快的细分市场 速效胰岛素
最大的市场 亚太地区

儘管前景可期，市场仍面临一个重大障碍：生物利用度低。人体胃部的恶劣生理环境会在胰岛素肽进入血液之前将其降解，导致吸收率低且治疗效果不稳定。这种生物屏障迫使研发人员设计复杂且昂贵的给药系统以确保疗效，这成为商业性应用和市场扩张的主要障碍。

市场驱动因素

全球糖尿病盛行率的不断上升是全球口服胰岛素市场的主要驱动力，也因此迫切需要开发传统注射剂以外的可扩展治疗方法。随着糖尿病患者人数的不断增长，医疗保健系统面临越来越大的压力，需要有效控制病情并预防与血糖控制不佳相关的併发症。根据美国疾病管制与预防中心 (CDC) 于 2024 年 5 月发布的《国家糖尿病统计报告》，美国约有 3,840 万人（占总人口的 11.6%）患有糖尿病。如此庞大的患者群体强烈表明，需要开发口服替代疗法来扩大治疗覆盖率并提高治疗可及性。此外，疾病管理不善造成的经济负担也引起了市场的关注。根据 Magellan Healthcare 于 2024 年 2 月发布的《处方笺困境》报告，因用药依从性差导致的疾病和死亡估计每年给医疗保健系统造成约 5284 亿美元的损失。

同时，研发投入的激增正在加速口服胰岛素的技术革新，以解决其生物有效性历来较低的问题。製药开发商正积极投资于新型递送平台，例如定向肝细胞的囊泡，这些囊泡旨在保护胰岛素免受胃部定向，并模拟人体自然的生理途径。这些投资对于将口服製剂从实验阶段推进商业性化产品阶段至关重要。例如，《克利夫兰商业周刊》在2024年1月报道称，Diasome Pharmaceuticals公司已获得950万美元的C轮资金筹措，用于推进其临床研发管线，包括扩展其口服定向肝细胞囊泡技术。这些投资凸显了製药业克服生物屏障、将有效口服胰岛素推向市场的决心。

市场挑战

低生物有效性是阻碍全球口服胰岛素市场商业性规模化发展的重大技术障碍。在胃部的强酸性环境中，蛋白水解酶会迅速降解胰岛素肽，导致只有极少量的活性药物进入血液。这种生物利用度低迫使生产商配製更高浓度的活性成分，并采用昂贵且复杂的包封技术，才能达到与标准注射剂相当的治疗浓度。因此，与成熟的低成本治疗方法相比，口服胰岛素的生产成本仍然过高，最终产品在经济上难以大规模应用。

由于需要克服生物利用度问题，导致价格差异巨大，这严重阻碍了糖尿病管理需求最高但医疗预算有限的地区的市场渗透。无法提供具有成本竞争力的替代方案，使得大量优先考虑价格因素的潜在患者群体望而却步。国际糖尿病联盟（IDF）的数据显示，到2024年，超过81%的糖尿病成人患者将居住在中低收入国家。这项数据表明，全球目标市场的大多数成员无法承担因生物利用度挑战而导致的高昂价格，从而抑制了市场的广泛扩张。

市场趋势

奈米颗粒包封技术的应用提高了口服胰岛素的生物有效性利用度，解决了胃酸降解这个关键难题，正在革新全球口服胰岛素市场。製造商越来越多地采用先进的脂质和聚合物基奈米载体，以保护胰岛素肽免受胃酸的侵蚀，并促进其在肠道内的靶向释放。与传统製剂相比，这项技术突破显着提高了吸收率，使市场更接近实现可行的无针给药方案。例如，根据发表在2025年12月MDPI期刊上的论文《基于奈米颗粒的口服胰岛素递送：挑战、进展和未来方向》，近期临床前研究表明，使用新型两性离子胶束奈米载体的口服胰岛素在糖尿病模型中实现了42.6%的生物利用度，较传统给药方法有了显着提高。

同时，策略合作开发伙伴关係和授权协议正成为加速商业化和降低高昂研发成本的重要机制。製药公司正与专业的生物技术公司合作，共用资源，以利用专有的递送平台和生产能力，尤其是在后期临床试验检验方面。旨在利用新兴地区生产效率的跨国合作凸显了这一趋势。一个典型的例子是欧瑞德製药（Oramed Pharmaceuticals）于2025年2月发布的新闻稿，宣布成立「变革性合资企业，加速口服胰岛素的开发和商业化」。新闻稿指出，欧瑞德製药将与合肥天辉生物技术有限公司（HTIT）共同投资7,500万美元，成立一家新的合资企业，旨在将口服胰岛素候选药物推向全球市场。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球口服胰岛素市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按剂型（片剂/胶囊）
    • 依胰岛素类型（长效胰岛素、短效胰岛素、速效胰岛素）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美口服胰岛素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲口服胰岛素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区口服胰岛素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲口服胰岛素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

10. 南美洲口服胰岛素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球口服胰岛素市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi SA
  • Biocon Limited
  • Wockhardt Limited
  • Gulf Pharmaceutical Industries
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • B. Braun Melsungen AG
  • Pfizer Inc.
  • Ypsomed AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 8025

The Global Insulin Pills Market is projected to grow from USD 0.04 Billion in 2025 to USD 0.15 Billion by 2031, expanding at a CAGR of 24.64%. This market focuses on the development of oral insulin formulations engineered to withstand gastric acidity and be absorbed through the intestines, acting as a non-invasive substitute for injections. Key drivers of this growth include the critical need for painless drug delivery methods to improve patient adherence and the rising global incidence of diabetes. Data from the International Diabetes Federation indicates that in 2024, approximately 589 million adults aged 20 to 79 were living with diabetes worldwide, highlighting the substantial demand for accessible therapeutic options.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 0.04 Billion
Market Size 2031USD 0.15 Billion
CAGR 2026-203124.64%
Fastest Growing SegmentRapid-Acting Insulin
Largest MarketAsia Pacific

Despite this promise, the market faces a significant obstacle in the form of low bioavailability. The harsh physiological environment of the human stomach breaks down insulin peptides before they can enter the bloodstream, resulting in poor absorption rates and unreliable therapeutic outcomes. This biological hurdle forces developers to engineer complex and expensive delivery systems to guarantee efficacy, serving as a major impediment to widespread commercial viability and overall market expansion.

Market Driver

The escalating global prevalence of Diabetes Mellitus serves as the primary engine driving the Global Insulin Pills Market, creating an urgent need for scalable treatment options beyond traditional injectables. As diabetes rates rise, healthcare systems are under increasing pressure to manage the disease effectively and prevent complications linked to uncontrolled hyperglycemia. According to the Centers for Disease Control and Prevention's 'National Diabetes Statistics Report' from May 2024, approximately 38.4 million people in the United States, or 11.6% of the population, have diabetes. This massive patient base underscores the critical necessity for oral alternatives that can enhance therapeutic reach and accessibility. Additionally, the economic burden of poor disease management drives market interest; the 'Prescription Predicament' report by Magellan Health in February 2024 estimates that morbidity and mortality associated with poor medication adherence cost the healthcare system roughly $528.4 billion annually.

Simultaneously, a surge in Research and Development investments is hastening the technological evolution of oral insulin, addressing the historical issue of low bioavailability. Pharmaceutical developers are aggressively funding novel delivery platforms, such as hepatocyte-directed vesicles, designed to protect insulin from gastric degradation and mimic the body's natural physiological pathways. These investments are essential for moving oral formulations from experimental stages to commercially viable products. For example, Crain's Cleveland Business reported in January 2024 that Diasome Pharmaceuticals secured $9.5 million in Series C financing to advance its clinical pipeline, including efforts to expand its oral hepatocyte-directed vesicle technology. Such financial commitments highlight the industry's dedication to overcoming biological barriers and bringing effective oral insulin to market.

Market Challenge

Low bioavailability represents a formidable technical barrier that directly hinders the commercial scalability of the Global Insulin Pills Market. In the harsh acidic environment of the stomach, proteolytic enzymes rapidly degrade insulin peptides, resulting in a negligible amount of the drug effectively entering the bloodstream. This biological inefficiency compels manufacturers to incorporate significantly higher quantities of active pharmaceutical ingredients and utilize expensive, complex encapsulation technologies to achieve therapeutic levels comparable to standard injectables. Consequently, the production cost of oral insulin remains disproportionately high, making the final product economically unviable for mass adoption compared to established, lower-cost therapies.

This price disparity, driven by the need to overcome bioavailability issues, severely restricts market penetration in regions where the demand for diabetes management is highest but healthcare budgets are constrained. The inability to offer a cost-competitive alternative alienates a vast segment of the potential patient base that prioritizes affordability. According to the International Diabetes Federation, in 2024, more than 81% of adults living with diabetes resided in low- and middle-income countries. This statistic highlights that the majority of the global target market cannot afford the premium pricing dictated by the bioavailability challenge, thereby stalling widespread market expansion.

Market Trends

The adoption of Nanoparticle Encapsulation Technologies to enhance bioavailability is revolutionizing the Global Insulin Pills Market by addressing the critical challenge of gastric degradation. Manufacturers are increasingly utilizing advanced lipid and polymer-based nanocarriers that protect insulin peptides from harsh stomach acidity and facilitate targeted release in the intestine. This technological leap significantly improves absorption rates compared to traditional formulations, moving the market closer to a viable needle-free alternative. For instance, according to MDPI, December 2025, in the 'Nanoparticle-Based Oral Insulin Delivery: Challenges, Advances, and Future Directions' article, recent pre-clinical studies demonstrated that insulin delivered orally via novel zwitterionic micelle nanocarriers achieved a bioavailability of 42.6% in diabetic models, a marked improvement over conventional delivery methods.

Simultaneously, Strategic Co-Development Partnerships and Licensing Agreements are becoming a pivotal mechanism for accelerating commercialization and mitigating high research costs. Pharmaceutical companies are pooling resources with specialized biotechnology firms to leverage proprietary delivery platforms and manufacturing capabilities, particularly for late-stage clinical validation. This trend is exemplified by cross-border collaborations aiming to tap into manufacturing efficiencies in emerging regions. A prime example is highlighted by Oramed Pharmaceuticals, February 2025, in the 'Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin' press release, which noted that Oramed and Hefei Tianhui Biotech (HTIT) committed a combined $75 million to a new joint venture focused on bringing their oral insulin candidate to the global market.

Key Market Players

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi S.A.
  • Biocon Limited
  • Wockhardt Limited
  • Gulf Pharmaceutical Industries
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • B. Braun Melsungen AG
  • Pfizer Inc.
  • Ypsomed AG

Report Scope

In this report, the Global Insulin Pills Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Insulin Pills Market, By Form

  • Tablet v/s Capsule

Insulin Pills Market, By Type of Insulin

  • Long-Acting Insulin
  • Short-Acting Insulin
  • Rapid-Acting Insulin

Insulin Pills Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Insulin Pills Market.

Available Customizations:

Global Insulin Pills Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Insulin Pills Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Form (Tablet v/s Capsule)
    • 5.2.2. By Type of Insulin (Long-Acting Insulin, Short-Acting Insulin, Rapid-Acting Insulin)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Insulin Pills Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Form
    • 6.2.2. By Type of Insulin
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Insulin Pills Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Form
        • 6.3.1.2.2. By Type of Insulin
    • 6.3.2. Canada Insulin Pills Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Form
        • 6.3.2.2.2. By Type of Insulin
    • 6.3.3. Mexico Insulin Pills Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Form
        • 6.3.3.2.2. By Type of Insulin

7. Europe Insulin Pills Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Form
    • 7.2.2. By Type of Insulin
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Insulin Pills Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Form
        • 7.3.1.2.2. By Type of Insulin
    • 7.3.2. France Insulin Pills Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Form
        • 7.3.2.2.2. By Type of Insulin
    • 7.3.3. United Kingdom Insulin Pills Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Form
        • 7.3.3.2.2. By Type of Insulin
    • 7.3.4. Italy Insulin Pills Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Form
        • 7.3.4.2.2. By Type of Insulin
    • 7.3.5. Spain Insulin Pills Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Form
        • 7.3.5.2.2. By Type of Insulin

8. Asia Pacific Insulin Pills Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Form
    • 8.2.2. By Type of Insulin
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Insulin Pills Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Form
        • 8.3.1.2.2. By Type of Insulin
    • 8.3.2. India Insulin Pills Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Form
        • 8.3.2.2.2. By Type of Insulin
    • 8.3.3. Japan Insulin Pills Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Form
        • 8.3.3.2.2. By Type of Insulin
    • 8.3.4. South Korea Insulin Pills Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Form
        • 8.3.4.2.2. By Type of Insulin
    • 8.3.5. Australia Insulin Pills Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Form
        • 8.3.5.2.2. By Type of Insulin

9. Middle East & Africa Insulin Pills Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Form
    • 9.2.2. By Type of Insulin
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Insulin Pills Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Form
        • 9.3.1.2.2. By Type of Insulin
    • 9.3.2. UAE Insulin Pills Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Form
        • 9.3.2.2.2. By Type of Insulin
    • 9.3.3. South Africa Insulin Pills Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Form
        • 9.3.3.2.2. By Type of Insulin

10. South America Insulin Pills Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Form
    • 10.2.2. By Type of Insulin
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Insulin Pills Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Form
        • 10.3.1.2.2. By Type of Insulin
    • 10.3.2. Colombia Insulin Pills Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Form
        • 10.3.2.2.2. By Type of Insulin
    • 10.3.3. Argentina Insulin Pills Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Form
        • 10.3.3.2.2. By Type of Insulin

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Insulin Pills Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novo Nordisk A/S
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Eli Lilly and Company
  • 15.3. Sanofi S.A.
  • 15.4. Biocon Limited
  • 15.5. Wockhardt Limited
  • 15.6. Gulf Pharmaceutical Industries
  • 15.7. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 15.8. B. Braun Melsungen AG
  • 15.9. Pfizer Inc.
  • 15.10. Ypsomed AG

16. Strategic Recommendations

17. About Us & Disclaimer